Media & News

Latest News

  • Living Cell Technologies Restructures
    Living Cell Technologies Limited has completed a strategic restructure of its business. The new organisation strengthens the capability of LCT’s 50 percent owned joint venture company Diatranz Otsuka Limited (DOL) and enables LCT to focus on development of new clinical products from its existing technology and intellectual property portfolio.
    Download PDF version
  • Half yearly report ended 31 December 2013
    Download PDF version
  • Statement on NTCELL Phase I clinical trial
    Living Cell Technologies Limited provides the following statement of facts regarding the withdrawal from publication of a preclinical study of NTCELL and the impact of this on the clinical trial currently underway at Auckland City Hospital.
    Download PDF version
  • Appointment of NTCELL Program Director
    Living Cell Technologies Limited (LCT) has appointed Dr Ken Taylor as NTCELL® Program Director. Dr Taylor will develop and manage the NTCELL clinical development program, ensuring the effective delivery of product development strategy and associated clinical trials.
    Download PDF version
  • Appendix 4C Quarterly Cash Flow Report 31 December 2013

    Download PDF version
  • Executive Change
    Dr Paul Tan retires today from his role as Chief Science and Medical Officer of Living Cell Technologies.
    Download PDF version